RxDoctor Payments Data

Zafirah Salman, MD

Pulmonary Disease · North Little Rock, ARNPI 1003256835

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,899 of the $18,033 with a category attached, or 60.4%. 40 manufacturers reported payments, led by Intuitive Surgical at 31.1% of the total. 2025 is the largest year on record at $7,994, 3.1 times the $2,604 reported in 2019. Among pulmonary disease clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,033in general payments, 2019–2025

Across 549 payments — averaging $32.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • Covidien LP$2K
  • GSK$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$984
  • Actelion Pharmaceuticals US, Inc.$788
  • plus $5K from 34 others

What the payments were for

  • Travel & lodging$2,83116%
  • Food & beverage$10,89960%
  • Education$4,30324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,033 in reported general payments places this provider in the 90th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$132,512
Medicare patients
448
Services billed
1,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter203$148,305
Dupixent PenDupilumab33$132,265
Breztri AerosphereBudesonide/Glycopyr/Formoterol57$44,695
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr79$37,159
Stiolto RespimatTiotropium Br/Olodaterol Hcl52$32,995
EliquisApixaban24$29,882
Breo ElliptaFluticasone/Vilanterol61$25,451
Spiriva RespimatTiotropium Bromide44$24,881
Incruse ElliptaUmeclidinium Bromide57$20,167
Advair HfaFluticasone Propion/Salmeterol43$15,174
Spiriva HandihalerTiotropium Bromide16$13,473
SymbicortBudesonide/Formoterol Fumarate31$9,303
Arnuity ElliptaFluticasone Furoate42$8,687
Bevespi AerosphereGlycopyrrolate/Formoterol Fum17$6,888
Albuterol Sulfate HfaAlbuterol Sulfate158$4,332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$1,941$239,770442 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,382$60,887105 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$984$57,87696 claims
PfizerEliquis$95$29,88224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 102 pulmonary disease providers in Arkansas.

Other pulmonary disease in North Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →